The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles
Open accessAbstract
The hypothesis that FasL expression by tumor cells may impair the in vivo efficacy of antitumor immune responses, through a mechanism known as ‘Fas tumor counterattack,’ has been recently questioned, becoming the object of an intense debate based on conflicting results. Here we definitely show that FasL is indeed detectable in the cytoplasm of melanoma cells and its expression is confined to multivesicular bodies that contain melanosomes. In these structures FasL colocalizes with both melanosomal (i.e., gp100) and lysosomal (i.e., CD63) antigens. Isolated melanosomes express FasL, as detected by Western blot and cytofluorimetry, and they can exert Fas-mediated apoptosis in Jurkat cells. We additionally show that melanosome-containing multivesicular bodies degranulate extracellularly and release FasL-bearing microvesicles, that coexpress both gp100 and CD63 and retain their functional activity in triggering Fas-dependent apoptosis of lymphoid cells. Hence our data provide evidence for a novel mechanism potentially operating in Fas tumor counterattack through the secretion of subcellular particles expressing functional FasL. Such vesicles may form a sort of front line hindering lymphocytes and other immunocompetent cells from entering neoplastic lesions and exert their antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,078
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Théry, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., et al. (2001) · Nature Medicine · doi:10.1038/85438 · Cited by 1,640
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
A TECHNIQUE FOR ULTRACRYOTOMY OF CELL SUSPENSIONS AND TISSUES
Tokuyasu, K. T. (1973) · The Journal of Cell Biology · doi:10.1083/jcb.57.2.551 · Cited by 1,074
Exosome: from internal vesicle of the multivesicular body to intercellular signaling device
Denzer, K., Kleijmeer, M. J., Heijnen, H. F. G., Stoorvogel, W., & Geuze, H. J. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.19.3365 · Cited by 1,067
Metalloproteinase-mediated release of human Fas ligand.
Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., & Yagita, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1777 · Cited by 822
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Downregulation of Fas ligand by shedding
Tanaka, M., Itai, T., Adachi, M., & Nagata, S. (1998) · Nature Medicine · doi:10.1038/nm0198-031 · Cited by 669
Dell'Angelica, E. C., Mullins, C., Caplan, S., & Bonifacino, J. S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1265 · Cited by 503
The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity
Siegel, R. M., Ka-Ming Chan, F., Chun, H. J., & Lenardo, M. J. (2000) · Nature Immunology · doi:10.1038/82712 · Cited by 431
Bossi, G., & Griffiths, G. M. (1999) · Nature Medicine · doi:10.1038/4779 · Cited by 387
Bennett, M. W., O’Connell, J., O’Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., & Shanahan, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5669 · Cited by 326
Antitumor effect of locally produced CD95 ligand
Seino, K.-I., Kayagaki, N., Okumura, K., & Yagita, H. (1997) · Nature Medicine · doi:10.1038/nm0297-165 · Cited by 312
Activated Human T Cells Release Bioactive Fas Ligand and APO2 Ligand in Microvesicles
Martínez-Lorenzo, M. J., Anel, A., Gamen, S., Monleón, I., Lasierra, P., Larrad, L., Piñeiro, A., Alava, M. A., & Naval, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.3.1274 · Cited by 307
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Restifo, N. P. (2000) · Nature Medicine · doi:10.1038/74955 · Cited by 251
A model for melanosome biogenesis based on the purification and analysis of early melanosomes
Kushimoto, T., Basrur, V., Valencia, J., Matsunaga, J., Vieira, W. D., Ferrans, V. J., Muller, J., Appella, E., & Hearing, V. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191184798 · Cited by 244
The Fas counterattack: Cancer as a site of immune privilege
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Collins, J. K., & Shanahan, F. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01382-6 · Cited by 232
Parlato, S., Giammarioli, A. M., Logozzi, M., Lozupone, F., Matarrese, P., Luciani, F., Falchi, M., Malorni, W., & Fais, S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.19.5123 · Cited by 217
Self-citationGastman, B., Atarshi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., & Whiteside, T. L. (1999) · PubMed · Cited by 216
Kiener, P. A., Davis, P. M., Rankin, B. M., Klebanoff, S. J., Ledbetter, J. A., Starling, G. C., & Liles, W. C. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.4.1594 · Cited by 201
Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis
Owen-Schaub, L. B., van Golen, K. L., Hill, L. L., & Price, J. E. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1717 · Cited by 168
Immune privilege or inflammation? Insights into the Fas ligand enigma
O’Connell, J., Houston, A. M., Bennett, M., O’Sullivan, G. C., & Shanahan, F. (2001) · Nature Medicine · doi:10.1038/85395 · Cited by 154
Okada, K., Komuta, K., Hashimoto, S., Matsuzaki, S., Kanematsu, T., & Koji, T. (2000) · PubMed · Cited by 99
Raisova, M., Bektas, M., Wieder, T., Daniel, P. T., Eberle, J., Orfanos, C. E., & Geilen, C. C. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01491-5 · Cited by 96
Constitutive Expression of FasL in Thyrocytes
Stokes, T. A., Rymaszewski, M., Arscott, P. L., Wang, S. H., Bretz, J. D., Bartron, J., & Baker, J. R. (1998) · Science · doi:10.1126/science.279.5359.2015a · Cited by 89
Favre-Félix, N., Fromentin, A., Hammann, A., Solary, É., Martin, F., & Bonnotte, B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5023 · Cited by 77
Munakata, S., Enomoto, T., Tsujimoto, M., Otsuki, Y., Miwa, H., Kanno, H., & Langrish, V. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1073 · Cited by 75
Countering the 'counterattack' hypothesis
Restifo, N. P. (2001) · Nature Medicine · doi:10.1038/85357 · Cited by 74
Apoptosis-inducing Membrane Vesicles
Jodo, S., Xiao, S., Hohlbaum, A. M., Strehlow, D., Marshak‐Rothstein, A., & Ju, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107005200 · Cited by 57
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
“FasL on melanoma or prostate cancerderived exosomes induces Fas-dependent apoptosis of T cells (85, 86).”
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Self-citationExosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346
Membrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882
Regulation of immune responses by extracellular vesicles
Robbins, P. D., & Morelli, A. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3622 · Cited by 2,260
Metadata
- Authors
- Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., Stringaro, A., Molinari, A., Arancia, G., Gentile, M., Parmiani, G., & Fais, S.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-05-20
- Volume
- 195
- Issue
- 10
- Pages
- 1303-1316
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2142598717
- Cited by
- 774
- References
- 32
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.